Temporary Medicare Coverage for Obesity Medications Set to Launch Amid Cost Concerns In a significant move to combat rising obesity rates, the Trump administration's temporary program to cover GLP-1 medications for Medicare beneficiaries is scheduled to kick off tomorrow and run through 2027. The initiative aims to provide coverage for these medications, which have been shown to be effective in weight loss, despite a long-standing federal ban on Medicare coverage for weight-loss drugs. However, with the program's launch comes uncertainty over its potential cost to taxpayers, with many questions still unanswered about how the program will be funded and how much it will ultimately cost the government. As the program gets underway, health experts and policymakers are closely watching to see how it will be implemented and what impact it will have on the nation's efforts to address the growing obesity epidemic.
Click in for more news from The Hill {beacon} Healthcare Health Care The Big Story Temporary Medicare GLP-1 coverage begins tomorrow The Trump administration’s temporary program to cover GLP-1 medications for obesity starts tomorrow and runs through 2027, but we still don’t know for sure how much it will cost taxpayers. © Adobe Stock Medicare is prohibited by law from covering weight-loss drugs but the...
